Uncover key drivers, emerging technologies, and competitive movements shaping the remote patient monitoring market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Breast Cancer Diagnostics Market expected to reach by 2030?

The breast cancer diagnostics market size has demonstrated significant expansion in recent years. This market is forecasted to increase from $5 billion in 2025 to $5.42 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.3%. The drivers behind this historical growth include the escalating global incidence of breast cancer, heightened awareness regarding early cancer screening, the expansion of diagnostic imaging infrastructure, the increasing availability of biomarker-based tests, and enhancements in the accuracy and safety of biopsies.

The breast cancer diagnostics market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $7.28 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.7%. This anticipated growth can be linked to several factors, including the increasing integration of precision oncology diagnostics, a surge in investments towards AI-powered diagnostic solutions, a heightened need for less invasive testing methods, the broadening scope of population-wide screening initiatives, and ongoing progress in molecular diagnostic technologies. Key developments anticipated during this period encompass the greater adoption of AI-supported imaging analysis, a growing prevalence of genomic and molecular tests, the expanded application of liquid biopsy procedures, an increase in sophisticated non-ionizing imaging options, and a stronger emphasis on early and customized diagnoses.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

What Drivers Are Driving Adoption Within The Breast Cancer Diagnostics Market?

Government initiatives and funding dedicated to breast cancer are projected to accelerate the expansion of the **breast cancer diagnostics market**. These governmental programs and financial assistance constitute a form of public financial backing provided to select entities whose ideas or projects contribute to public services and economic enhancement. Such efforts are vital in supporting breast cancer research, prevention, and treatment, through various programs designed to elevate awareness, encourage early detection via screening and mammography, and deliver financial aid for testing and care to underserved communities. As an illustration, **The Australian Government Department of Health (DoH)**, an Australia-based government agency, earmarked **$40.7 million** in its budget for **2022-23** to bolster access to testing and screening services for diverse cancer types. This allocation aims to mitigate delays caused by the COVID-19 pandemic and ensure timely referrals, prompt diagnoses, and early interventions, with **$9.7 million** of this sum specifically directed towards breast cancer screening. Consequently, these governmental undertakings and financial provisions for breast cancer are actively stimulating the growth of the **breast cancer diagnostics market**.

How Is The Breast Cancer Diagnostics Market Organized Into Various Segments?

The breast cancer diagnostics market covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, Triple-Negative Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

Which Trends Are Influencing The Performance And Direction Of The Breast Cancer Diagnostics Market?

Key companies within the breast cancer diagnostics market are prioritizing the creation of innovative AI-powered diagnostic solutions, including advanced pathology scoring platforms, to elevate accuracy, optimize operational flows, and facilitate personalized treatment approaches. AI-based diagnostic platforms encompass technologies that leverage machine learning and deep-learning algorithms to examine medical imaging, pathology slides, or clinical information, providing diagnostic insights or risk categorizations that assist clinical decision-making. For example, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, unveiled its expanded AI platform for breast cancer diagnostics. This launch introduced a fully automated, zero-click HER2 immunohistochemistry (IHC) scoring feature within its Ibex Breast HER2 module. This instrument identifies invasive cancer zones, categorizes HER2 expression levels (0, 1+, 2+, 3+), and supports breast cancer diagnosis and treatment-pathway choices with heightened precision and workflow effectiveness.

Who Are The Primary Competitors In The Global Breast Cancer Diagnostics Market?

Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Breast Cancer Diagnostics Market?

North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Breast Cancer Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3284&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Diagnostics Market 2026, By The Business Research Company

Next Generation Gynecological Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Breast Imaging Technologies Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-imaging-technologies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company